Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Completed PHASE1 INTERVENTIONAL NCT04940078

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections. The aim of the study is to find out how the different ways of injection affect the level of the medicines in the blood. For the first 14 weeks of the study, participants will get cagrilintide and semaglutide as 2 separate injections. Then participants will either switch to getting the medicines as a combined injection or continue to get the separate injections for 8 weeks. Which treatment participants get after the first 14 weeks is decided by chance. Participants will get the study medicines once a week for 22 weeks. A study nurse at the clinic will inject the medicines with a thin needle in participants stomach area. The study will last for about 8 months.Participants will have 28 clinic visits with the study staff. For 4 of these visits, participants will stay in the clinic for 5 nights. Participants will have blood drawn at 21 visits. Participants will have clinical assessments and participants will be asked about their health, medical history and habits including mental health questionnaires. For women: Participants must not be able to become pregnant if they wish to participate in this study.

Interventions

Name: Cagrilintide
Type: DRUG
Description: Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
Name: semaglutide
Type: DRUG
Description: Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
Name: Cagrilintide and semaglutide
Type: DRUG
Description: Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe

Primary Outcomes

Measure: AUC0-168h,cagri,2.4/2.4mg,SS area under the cagrilintide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg
TimeFrame: Day 148 (pre-dose) to Day 155 (168 hours post-dose)
Description: measured in nmol⸱h/L
Measure: Cmax,cagri,2.4/2.4mg,SS maximum concentration of cagrilintide at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg
TimeFrame: Day 148 (pre-dose) to Day 155 (168 hours post-dose)
Description: measured in nmol/L
Measure: AUC0-168h,sema,2.4/2.4mg,SS area under the semaglutide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg
TimeFrame: Day 148 (pre-dose) to Day 155 (168 hours post-dose)
Description: measured in nmol⸱h/L
Measure: Cmax,sema,2.4/2.4mg,SS maximum concentration of semaglutide at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg
TimeFrame: Day 148 (pre-dose) to Day 155 (168 hours post-dose)
Description: measured in nmol/L

Trial Information

NCT ID

NCT04940078

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025